Shrunken Pore Syndrome Is Associated With Increased Levels of Atherosclerosis-Promoting Proteins

Introduction: Shrunken pore syndrome (SPS), originally defined by cystatin C−based estimated glomerular filtration rate (eGFRcystatin C) being less than 60% of creatinine-based estimated glomerular filtration rate (eGFRcreatinine) in the absence of extrarenal influences on the plasma levels of cysta...

Full description

Bibliographic Details
Main Authors: Markus Sällman Almén, Jonas Björk, Ulf Nyman, Veronica Lindström, Magnus Jonsson, Magnus Abrahamson, AnnaLotta Schiller Vestergren, Örjan Lindhe, Gary Franklin, Anders Christensson, Anders Grubb
Format: Article
Language:English
Published: Elsevier 2019-01-01
Series:Kidney International Reports
Online Access:http://www.sciencedirect.com/science/article/pii/S2468024918302006
id doaj-1aeb9e4edf704a6ebdd5be7db0b828f7
record_format Article
spelling doaj-1aeb9e4edf704a6ebdd5be7db0b828f72020-11-25T01:08:40ZengElsevierKidney International Reports2468-02492019-01-01416779Shrunken Pore Syndrome Is Associated With Increased Levels of Atherosclerosis-Promoting ProteinsMarkus Sällman Almén0Jonas Björk1Ulf Nyman2Veronica Lindström3Magnus Jonsson4Magnus Abrahamson5AnnaLotta Schiller Vestergren6Örjan Lindhe7Gary Franklin8Anders Christensson9Anders Grubb10Olink Proteomics, Uppsala, SwedenDepartment of Occupational and Environmental Medicine, Lund University, Lund, SwedenDepartment of Clinical Sciences, Lund University, Malmö, SwedenDepartment of Clinical Chemistry, Skåne University Hospital, Lund, Lund University, SwedenDepartment of Clinical Chemistry, Skåne University Hospital, Malmö, SwedenDepartment of Laboratory Medicine, Lund University, Lund, SwedenOlink Proteomics, Uppsala, SwedenOlink Proteomics, Uppsala, SwedenOlink Proteomics, Uppsala, SwedenDepartment of Nephrology, Skåne University Hospital, Malmö, Lund University, SwedenDepartment of Clinical Chemistry, Skåne University Hospital, Lund, Lund University, Sweden; Correspondence: Anders Grubb, Department of Clinical Chemistry, Skåne University Hospital, Lund University, SE-22185 Lund, Sweden.Introduction: Shrunken pore syndrome (SPS), originally defined by cystatin C−based estimated glomerular filtration rate (eGFRcystatin C) being less than 60% of creatinine-based estimated glomerular filtration rate (eGFRcreatinine) in the absence of extrarenal influences on the plasma levels of cystatin C or creatinine, is associated with a high increase in mortality, even in the absence of reduced glomerular filtration rate (GFR). The objective of the present study was to determine whether the proteome of patients with SPS shows differences from that of patients with normal or reduced measured GFR (mGFR) without SPS. Methods: Four patient cohorts were included: 1 cohort with normal mGFR without SPS, 1 with normal mGFR with SPS, 1 with reduced mGFR without SPS, and 1 with reduced mGFR with SPS. The plasma levels of 177 selected proteins were analyzed. Results: Differences in the levels of 30 proteins were specific for SPS; 31 differences were specific for patients with both SPS and reduced mGFR; and 27 were specific for reduced mGFR. Eighteen of the differences specific for SPS concerned proteins described as promoting, or being associated with, atherosclerosis. Twelve of the differences specific for patients with both SPS and reduced mGFR and 10 of the differences specific for reduced mGFR also concerned proteins described as promoting, or being associated with, atherosclerosis. Almost all (82 of 88) of the concentration differences represented increased levels. For SPS, but not for reduced mGFR, a correlation between protein size and increase in level was observed, with smaller proteins being associated with higher levels. Conclusion: The high mortality in shrunken pore syndrome might be caused by the accumulation of atherosclerosis-promoting proteins in this condition. Keywords: atherosclerosis, creatinine, cystatin C, GFR, kidney, mortalityhttp://www.sciencedirect.com/science/article/pii/S2468024918302006
collection DOAJ
language English
format Article
sources DOAJ
author Markus Sällman Almén
Jonas Björk
Ulf Nyman
Veronica Lindström
Magnus Jonsson
Magnus Abrahamson
AnnaLotta Schiller Vestergren
Örjan Lindhe
Gary Franklin
Anders Christensson
Anders Grubb
spellingShingle Markus Sällman Almén
Jonas Björk
Ulf Nyman
Veronica Lindström
Magnus Jonsson
Magnus Abrahamson
AnnaLotta Schiller Vestergren
Örjan Lindhe
Gary Franklin
Anders Christensson
Anders Grubb
Shrunken Pore Syndrome Is Associated With Increased Levels of Atherosclerosis-Promoting Proteins
Kidney International Reports
author_facet Markus Sällman Almén
Jonas Björk
Ulf Nyman
Veronica Lindström
Magnus Jonsson
Magnus Abrahamson
AnnaLotta Schiller Vestergren
Örjan Lindhe
Gary Franklin
Anders Christensson
Anders Grubb
author_sort Markus Sällman Almén
title Shrunken Pore Syndrome Is Associated With Increased Levels of Atherosclerosis-Promoting Proteins
title_short Shrunken Pore Syndrome Is Associated With Increased Levels of Atherosclerosis-Promoting Proteins
title_full Shrunken Pore Syndrome Is Associated With Increased Levels of Atherosclerosis-Promoting Proteins
title_fullStr Shrunken Pore Syndrome Is Associated With Increased Levels of Atherosclerosis-Promoting Proteins
title_full_unstemmed Shrunken Pore Syndrome Is Associated With Increased Levels of Atherosclerosis-Promoting Proteins
title_sort shrunken pore syndrome is associated with increased levels of atherosclerosis-promoting proteins
publisher Elsevier
series Kidney International Reports
issn 2468-0249
publishDate 2019-01-01
description Introduction: Shrunken pore syndrome (SPS), originally defined by cystatin C−based estimated glomerular filtration rate (eGFRcystatin C) being less than 60% of creatinine-based estimated glomerular filtration rate (eGFRcreatinine) in the absence of extrarenal influences on the plasma levels of cystatin C or creatinine, is associated with a high increase in mortality, even in the absence of reduced glomerular filtration rate (GFR). The objective of the present study was to determine whether the proteome of patients with SPS shows differences from that of patients with normal or reduced measured GFR (mGFR) without SPS. Methods: Four patient cohorts were included: 1 cohort with normal mGFR without SPS, 1 with normal mGFR with SPS, 1 with reduced mGFR without SPS, and 1 with reduced mGFR with SPS. The plasma levels of 177 selected proteins were analyzed. Results: Differences in the levels of 30 proteins were specific for SPS; 31 differences were specific for patients with both SPS and reduced mGFR; and 27 were specific for reduced mGFR. Eighteen of the differences specific for SPS concerned proteins described as promoting, or being associated with, atherosclerosis. Twelve of the differences specific for patients with both SPS and reduced mGFR and 10 of the differences specific for reduced mGFR also concerned proteins described as promoting, or being associated with, atherosclerosis. Almost all (82 of 88) of the concentration differences represented increased levels. For SPS, but not for reduced mGFR, a correlation between protein size and increase in level was observed, with smaller proteins being associated with higher levels. Conclusion: The high mortality in shrunken pore syndrome might be caused by the accumulation of atherosclerosis-promoting proteins in this condition. Keywords: atherosclerosis, creatinine, cystatin C, GFR, kidney, mortality
url http://www.sciencedirect.com/science/article/pii/S2468024918302006
work_keys_str_mv AT markussallmanalmen shrunkenporesyndromeisassociatedwithincreasedlevelsofatherosclerosispromotingproteins
AT jonasbjork shrunkenporesyndromeisassociatedwithincreasedlevelsofatherosclerosispromotingproteins
AT ulfnyman shrunkenporesyndromeisassociatedwithincreasedlevelsofatherosclerosispromotingproteins
AT veronicalindstrom shrunkenporesyndromeisassociatedwithincreasedlevelsofatherosclerosispromotingproteins
AT magnusjonsson shrunkenporesyndromeisassociatedwithincreasedlevelsofatherosclerosispromotingproteins
AT magnusabrahamson shrunkenporesyndromeisassociatedwithincreasedlevelsofatherosclerosispromotingproteins
AT annalottaschillervestergren shrunkenporesyndromeisassociatedwithincreasedlevelsofatherosclerosispromotingproteins
AT orjanlindhe shrunkenporesyndromeisassociatedwithincreasedlevelsofatherosclerosispromotingproteins
AT garyfranklin shrunkenporesyndromeisassociatedwithincreasedlevelsofatherosclerosispromotingproteins
AT anderschristensson shrunkenporesyndromeisassociatedwithincreasedlevelsofatherosclerosispromotingproteins
AT andersgrubb shrunkenporesyndromeisassociatedwithincreasedlevelsofatherosclerosispromotingproteins
_version_ 1725182091507793920